Efficacy and safety analysis of transarterial chemoembolization and transarterial radioembolization in advanced hepatocellular carcinoma descending hepatectomy

Table 1 Comparison of general data in each group

	TACE group (n = 119)	TACE + TARE group (n = 99)	χ2	P value
Gender			0.512	0.604
Male	63	48
Female	56	51
Age (yr), mean ± SD	56.78 ± 5.68	55.89 ± 5.45	1.173	0.242
Child-Pagh liver function rating			0.463	0.765
Grade A	36	32
Grade B	60	42
Grade C	23	25
Tumor diameter			0.862	0.755
< 5 cm	48	42
< 5 cm	71	57

TACE: Transarterial chemoembolization; TARE: Transarterial radioembolization.

Table 2 Comparison of inactivation of lesions in Table 2 groups, n (%)

Group	CR	PR	NC	PD	The effective rate of treatment
TACE group (n = 119)	25 (21.01)	26 (21.84)	38 (26.89)	30 (18.49)	51 (42.86)
TACE + TARE group (n = 99)	34 (34.34)	34 (34.34)	16 (21.21)	15 (23.23)	68 (68.69)
χ2	0.040	0.057	0.011	0.097	< 0.001
P value	0.027	0.040	0.007	0.068	< 0.001

CR: Complete remission; PR: Partial remission; NC: Nature change; PD: Progress development.

Table 3 Comparison of tumor nodules in groups, n (%)

Group	Tumor nodules
	> 50%	< 50%	Stable	Increase
TACE group (n = 119)	39 (32.78)	28 (23.53)	29 (24.37)	23 (19.33)
TACE + TARE group (n = 99)	20 (20.20)	36 (36.36)	37 (37.37)	6 (6.06)
χ2	0.054	0.041	0.053	0.008
P value	0.038	0.028	0.037	0.004

TACE: Transarterial chemoembolization; TARE: Transarterial radioembolization.

Table 4 Comparison of lipiodol deposition in groups, n (%)

Group	Lipiodol deposition
	Grade 0	Grade I	Grade II	Grade III	Grade IV	Grade III + IV
TACE group (n = 119)	18 (29.41)	23 (29.41)	20 (21.85)	30 (25.21)	28 (23.53)	58 (48.74)
TACE + TARE group (n = 99)	8 (29.41)	8 (11.11)	10 (15.15)	38 (38.38)	35 (35.35)	63 (63.64)
χ2	0.165	0.030	0.152	0.037	0.045	< 0.001
P value	0.110	0.018	0.217	0.052	0.077	< 0.001

TACE: Transarterial chemoembolization; TARE: Transarterial radioembolization.

Table 5 Comparison of serum alpha-fetoprotein levels in different stages (mean ± SD)

Group	AFP (μg/L)
	1 mo after the operation	3 mo after the operation	6 mo after the operation	1 year after the operation
TACE group (n = 119)	38.33 ± 4.78	38.67 ± 5.32	36.45 ± 3.24	31.53 ± 3.54
TACE + TARE group (n = 99)	36.45 ± 5.68	35.53 ± 4.45	32.37 ± 3.47	28.78 ± 3.25
χ2	2.654	4.669	8.963	5.926
P value	0.009	< 0.001	< 0.001	< 0.001

AFP: Alpha-fetoprotein; TACE: Transarterial chemoembolization; TARE: Transarterial radioembolization.

Table 6 Comparison of postoperative complications and 1-year survival rate in groups, n (%)

Complications	TACE group (n = 119)	TACE + TARE group (n = 99)	χ2	P value
Fever	6 (5.04)	6 (6.06)	0.976	0.743
Hydrothorax	16 (13.45)	15 (5.05)	0.869	0.720
Cholecystitis	4 (3.36)	6 (6.06)	0.533	0.343
Hepatic encephalopathy	15 (12.61)	9 (9.09)	0.543	0.409
Total complication rate	41 (34.45)	36 (36.37)	0.880	0.769
1-yr survival rate	25 (21.00)	33 (33.33)	0.058	0.040

TACE: Transarterial chemoembolization; TARE: Transarterial radioembolization.

Table 7 Clinical symptom score (mean ± SD)

Group	Hepatic pain		Fatigue		Abdominal distension
	Before treatment	After treatment	Before treatment	After treatment	Before treatment	After treatment
TACE group (n = 119)	2.31 ± 0.56	2.07 ± 0.63	2.67 ± 0.87	2.35 ± 0.54	2.93 ± 0.62	2.37 ± 0.55
TACE + TARE group (n = 99)	2.29 ± 0.58	1.56 ± 0.72	2.54 ± 0.58	1.45 ± 0.63	2.79 ± 0.58	1.26 ± 0.66
χ2	0.258	5.576	0.720	11.357	1.709	13.545
P value	0.796	< 0.05	0.205	< 0.001	0.089	< 0.001

TACE: Transarterial chemoembolization; TARE: Transarterial radioembolization.

Table 8 Comparison of adverse reactions in groups, n (%)

Group	Nausea	Vomiting	Hair loss	Total incidence
TACE group (n = 119)	11 (9.24)	9 (7.56)	10 (8.40)	30 (25.21)
TACE + TARE group (n = 99)	5 (5.05)	5 (5.05)	4 (4.04)	14 (14.14)
χ2	0.357	0.634	0.303	0.063
P value	0.237	0.451	0.191	0.043

TACE: Transarterial chemoembolization; TARE: Transarterial radioembolization.